SEC Form 4 · accession 0001209191-18-007711
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven J Mento
Director
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 8:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2018 | M | 5,000 | $6.41 | A | 5,000 | D | |
| Common Stock | Feb 1, 2018 | M | 10,000 | $10.17 | A | 15,000 | D | |
| Common StockF2 | Feb 1, 2018 | S | 11,520 | $20.5867 | D | 3,480 | D | |
| Common StockF3 | holding | — | — | — | 32,214 | I | By Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $6.41 | Feb 1, 2018 | M | 5,000 | D | — | May 31, 2021 | Common Stock | 5,000 | 5,000 | D |
| StockOption (Right to Buy)F4 | $10.17 | Feb 1, 2018 | M | 10,000 | D | — | Jun 4, 2018 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2017.
- F2The price reported is a weighted average price. The shares were sold at prices ranging from $20.25 to $20.90 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3These shares are held in the Mento Family Trust by Steven J. Mento and Linda A. Mento, Trustees of the Mento Family Trust dated December 29, 1994.
- F4Fully vested and exercisable.